These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29432024)

  • 1. Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer.
    Perepelyuk M; Sacko K; Thangavel K; Shoyele SA
    Mol Pharm; 2018 Mar; 15(3):985-993. PubMed ID: 29432024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins.
    Perepelyuk M; Maher C; Lakshmikuttyamma A; Shoyele SA
    Int J Nanomedicine; 2016; 11():3533-44. PubMed ID: 27555773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates.
    Sacko K; Thangavel K; Shoyele SA
    Nanomaterials (Basel); 2019 Jul; 9(7):. PubMed ID: 31340494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.
    Dai F; Zhang Y; Zhu X; Shan N; Chen Y
    Target Oncol; 2012 Dec; 7(4):217-25. PubMed ID: 23179556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism involved in the loss of PTEN expression in NSCLC tumor cells.
    Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
    Biochem Biophys Res Commun; 2012 Feb; 418(3):547-52. PubMed ID: 22290228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
    Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK; Blum W; Perrotti D; Byrd JC; Bloomfield CD; Caligiuri MA; Lee RJ; Garzon R; Muthusamy N; Lee LJ; Marcucci G
    Clin Cancer Res; 2013 May; 19(9):2355-67. PubMed ID: 23493348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer.
    Dai F; Zhang Y; Zhu X; Shan N; Chen Y
    Gynecol Oncol; 2013 Nov; 131(2):451-9. PubMed ID: 23933187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
    Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
    Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
    Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
    J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells.
    Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H
    Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells.
    Wang H; Zhao X; Guo C; Ren D; Zhao Y; Xiao W; Jiao W
    PLoS One; 2015; 10(9):e0139136. PubMed ID: 26406332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide.
    Charbgoo F; Alibolandi M; Taghdisi SM; Abnous K; Soltani F; Ramezani M
    Nanomedicine; 2018 Apr; 14(3):685-697. PubMed ID: 29317345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo.
    Guo X; Wang W; Hu J; Feng K; Pan Y; Zhang L; Feng Y
    Anat Rec (Hoboken); 2012 Dec; 295(12):2114-21. PubMed ID: 22961798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
    Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
    Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
    Liu Y; Wu X; Gao Y; Zhang J; Zhang D; Gu S; Zhu G; Liu G; Li X
    Int J Nanomedicine; 2016; 11():3891-905. PubMed ID: 27574422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer.
    Esfandyari-Manesh M; Mohammadi A; Atyabi F; Nabavi SM; Ebrahimi SM; Shahmoradi E; Varnamkhasti BS; Ghahremani MH; Dinarvand R
    Int J Pharm; 2016 Dec; 515(1-2):607-615. PubMed ID: 27989825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas.
    Ghasemi Z; Dinarvand R; Mottaghitalab F; Esfandyari-Manesh M; Sayari E; Atyabi F
    Carbohydr Polym; 2015 May; 121():190-8. PubMed ID: 25659689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC-1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment.
    Zou Q; Zhang CJ; Yan YZ; Min ZJ; Li CS
    J Cell Biochem; 2019 Nov; 120(11):18650-18658. PubMed ID: 31338877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
    Yin H; Xiong G; Guo S; Xu C; Xu R; Guo P; Shu D
    Mol Ther; 2019 Jul; 27(7):1252-1261. PubMed ID: 31085078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer.
    Tan M; Wu J; Cai Y
    Biochem Biophys Res Commun; 2013 Sep; 438(4):673-9. PubMed ID: 23939044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.